BASEL, SWITZERLAND--(MARKET WIRE)--Jul 17, 2007 -- Basel, Switzerland, July 17, 2007 - Basilea Pharmaceutica Ltd. (Swiss:BSLN.SW - News) announced today the filing of a New Drug Submission (NDS) for ceftobiprole with the Therapeutic Products Directorate (TPD) of Health Canada by its license partner Janssen-Ortho, Inc., a Johnson & Johnson company. This submission is for the use of ceftobiprole in the treatment of complicated skin and skin structure infections (cSSSI).